Management of Malignant Pleural Mesothelioma

• Published in: Ankara Üniversitesi Tıp Fakültesi Mecmuası
• Main Authors: Mustafa Gürbüz, Güngör Utkan
• Format: Article
• Language: English
• Published: Ankara University Press 2019-04-01
• Subjects: Malignant Pleural Mesothelioma; Treatment; Chemotherapy; Targeted Therapy; Immunotherapy
• Online Access: http://ankaratipfakultesimecmuasi.net/archives/archive-detail/article-preview/management-of-malignant-pleural-mesothelioma/27741

Malignant mesothelioma (MM) arises from mesothelial surfaces of the pleural cavity, peritoneal cavity, tunica vaginalis, or pericardium. MM is a rare and insidious neoplasm with a poor prognosis. Malignant pleural mesothelioma (MPM) is the most common type and typically arises from the mesothelial surfaces of the pleural cavity. MPM can be difficult to treat because most patients have advanced disease at presentation. The median survival of patients is between 6 and 18 months. However, carefully selected patients with localized disease who receive aggressive multimodality therapy have relatively prolonged survival. In this review, we aimed to evaluate the results of surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy studies to improve survival in MPM.